Emtricitabine + tenofovir is a fixed-dose combination of nucleotide/nucleoside analog reverse-transcriptase inhibitors (NRTIs) used to prevent and treat HIV/AIDS.
Emtricitabine + tenofovir
EML status history
First added in 2007 (TRS 946) for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Added in 2017 (TRS 1006) for Contact with or exposure to human immunodeficiency virus
Therapeutic equivalent for
Fixed-dose combinations of antiretrovirals
- Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)